Literature DB >> 22346296

Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.

Jocelyn D Jones, Sylvia H Jackson, Carmen Agboton, Tonya S Martin.   

Abstract

Entities:  

Year:  2011        PMID： 22346296      PMCID： PMC3278144     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  6 in total

1.  Deaths preventable in the U.S. by improvements in use of clinical preventive services.

Authors:  Thomas A Farley; Mehul A Dalal; Farzad Mostashari; Thomas R Frieden
Journal:  Am J Prev Med       Date:  2010-06       Impact factor: 5.043

2.  Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.

Authors:  William B White; Michael A Weber; Domenic Sica; George L Bakris; Alfonso Perez; Charlie Cao; Stuart Kupfer
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

3.  Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Justin G Trogdon; Olga A Khavjou; Javed Butler; Kathleen Dracup; Michael D Ezekowitz; Eric Andrew Finkelstein; Yuling Hong; S Claiborne Johnston; Amit Khera; Donald M Lloyd-Jones; Sue A Nelson; Graham Nichol; Diane Orenstein; Peter W F Wilson; Y Joseph Woo
Journal:  Circulation       Date:  2011-01-24       Impact factor: 29.690

4.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

5.  The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.

Authors:  George L Bakris; Domenic Sica; Michael Weber; William B White; Andrew Roberts; Alfonso Perez; Charlie Cao; Stuart Kupfer
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-02       Impact factor: 3.738

6.  Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.

Authors:  Domenic Sica; William B White; Michael A Weber; George L Bakris; Alfonso Perez; Charlie Cao; Alison Handley; Stuart Kupfer
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-06-20       Impact factor: 3.738
  6 in total
  7 in total

Review 1.  Azilsartan medoxomil: a review of its use in hypertension.

Authors:  Caroline M Perry
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 2.859

Review 2.  Critical evaluation of the efficacy and tolerability of azilsartan.

Authors:  Alberto R De Caterina; Andrew R Harper; Florim Cuculi
Journal:  Vasc Health Risk Manag       Date:  2012-05-14

3.  The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.

Authors:  Peter Bramlage; Roland E Schmieder; Anselm K Gitt; Peter Baumgart; Felix Mahfoud; Hartmut Buhck; Taoufik Ouarrak; Martina Ehmen; Sebastian A Potthoff
Journal:  Trials       Date:  2015-12-19       Impact factor: 2.279

4.  Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.

Authors:  Caroline Dudkowski; Aziz Karim; Zhen Zhao; Alberto B Alonso; Dyal Garg; Richard A Preston
Journal:  J Clin Pharmacol       Date:  2017-07-27       Impact factor: 3.126

5.  The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure.

Authors:  Alfonso Perez; Charlie Cao
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-25       Impact factor: 3.738

6.  EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry.

Authors:  Anselm K Gitt; Peter Baumgart; Peter Bramlage; Felix Mahfoud; Sebastian A Potthoff; Jochen Senges; Steffen Schneider; Hartmut Buhck; Roland E Schmieder
Journal:  BMC Cardiovasc Disord       Date:  2013-07-02       Impact factor: 2.298

7.  Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry.

Authors:  Anselm K Gitt; Peter Bramlage; Sebastian A Potthoff; Peter Baumgart; Felix Mahfoud; Hartmut Buhck; Martina Ehmen; Taoufik Ouarrak; Jochen Senges; Roland E Schmieder
Journal:  BMC Cardiovasc Disord       Date:  2016-03-08       Impact factor: 2.298
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.